Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $233.18M |
| Net Income (Most Recent Fiscal Year) | $-321.55M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 39.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -82.60% |
| Net Margin (Trailing 12 Months) | -82.88% |
| Return on Equity (Trailing 12 Months) | -1179.73% |
| Return on Assets (Trailing 12 Months) | -41.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.05 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.03 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 9.46 |
| Inventory Turnover (Trailing 12 Months) | 1.94 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 88.81M |
| Free Float | 85.20M |
| Market Capitalization | $1.29B |
| Average Volume (Last 20 Days) | 1.59M |
| Beta (Past 60 Months) | 0.75 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.06% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |